Morgan Stanley’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$52.9K Sell
46,037
-56,561
-55% -$72K ﹤0.01% 6404
2025
Q4
$112K Buy
102,598
+4,899
+5% +$5.48K ﹤0.01% 6141
2025
Q3
$98.7K Sell
97,699
-368,931
-79% -$403K ﹤0.01% 6157
2025
Q2
$537K Buy
466,630
+355,040
+318% +$459K ﹤0.01% 5433
2025
Q1
$166K Buy
111,590
+56,996
+104% +$68.4K ﹤0.01% 5812
2024
Q4
$44.7K Buy
54,594
+54,200
+13,756% +$47.8K ﹤0.01% 6319
2024
Q3
$321 Sell
394
-560
-59% -$459 ﹤0.01% 7346
2024
Q2
$782 Sell
954
-22
-2% -$19 ﹤0.01% 7183
2024
Q1
$790 Buy
976
+576
+144% +$747 ﹤0.01% 7197
2023
Q4
$564 Buy
400
+200
+100% +$264 ﹤0.01% 7269
2023
Q3
$234 Hold
200
﹤0.01% 7373
2023
Q2
$278 Sell
200
-600
-75% -$904 ﹤0.01% 7425
2023
Q1
$1.12K Sell
800
-93
-10% -$129 ﹤0.01% 7337
2022
Q4
$1.21K Sell
893
-18,361
-95% -$33K ﹤0.01% 7443
2022
Q3
$30K Sell
19,254
-39,092
-67% -$97.3K ﹤0.01% 6621
2022
Q2
$131K Buy
58,346
+49,117
+532% +$109K ﹤0.01% 6129
2022
Q1
$31K Sell
9,229
-12,533
-58% -$45.8K ﹤0.01% 6937
2021
Q4
$116K Buy
+21,762
New +$177K ﹤0.01% 6352

Other funds holding LUCD

Morgan Stanley's LUCD Position: Q1 2026 in Review

Morgan Stanley reduced its Lucid Diagnostics (LUCD) stake by 55% in Q1 2026, selling an estimated $72K and leaving 46,037 shares worth $52.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6404.

Morgan Stanley first reported a position in LUCD in Q4 2021 and has held it in 18 quarters since. The position peaked at $537K in Q2 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Morgan Stanley held 46,037 shares of Lucid Diagnostics worth $52.9K as of Q1 2026.
  • Morgan Stanley sold 56,561 Lucid Diagnostics shares in Q1 2026, an estimated $72K.
  • Lucid Diagnostics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6404 holding.
  • Morgan Stanley first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 18 quarters since.
  • Morgan Stanley's Lucid Diagnostics position peaked at $537K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.